H L McLeod

Summary

Affiliation: Washington University School of Medicine
Country: USA

Publications

  1. ncbi request reprint Pharmacogenetic analysis of clinically relevant genetic polymorphisms
    Howard L McLeod
    Department of Medicine, The Alvin J Siteman Cancer Center, Washington University School of Medicine, St Louis, MO 63110, USA
    Clin Infect Dis 41:S449-52. 2005
  2. pmc CYP3A4 and CYP3A5 genotyping by Pyrosequencing
    Adam A Garsa
    Washington University School of Medicine, Department of Medicine, Division of Oncology, St Louis, MO 63110, USA
    BMC Med Genet 6:19. 2005
  3. ncbi request reprint Using genetic variation to optimize cancer chemotherapy
    Howard L McLeod
    Washington University School of Medicine, Siteman Cancer Center, St Louis, MO 63110, USA
    Clin Adv Hematol Oncol 1:107-11. 2003
  4. ncbi request reprint Cancer pharmacogenomics: SNPs, chips, and the individual patient
    Howard L McLeod
    Departments of Medicine, Molecular Biology and Pharmacology, and Genetics, Siteman Cancer Center, Washington University School of Medicine, St Louis, Missouri, USA
    Cancer Invest 21:630-40. 2003
  5. pmc Unfavourable expression of pharmacologic markers in mucinous colorectal cancer
    S C Glasgow
    Department of Surgery, Washington University School of Medicine, St Louis, MI, USA
    Br J Cancer 92:259-64. 2005
  6. ncbi request reprint Application of pharmacogenomics in the individualization of chemotherapy for gastrointestinal malignancies
    Howard L McLeod
    Department of Medicine and The Siteman Cancer Center, Washington University School of Medicine, St Louis, MO 63110 1093, USA
    Clin Colorectal Cancer 4:S43-7. 2004
  7. ncbi request reprint Molecular predictors of prognosis and response to therapy in colorectal cancer
    Howard L McLeod
    Washington University School of Medicine, Department of Medicine, St Louis, MO 63110 1093, USA
    Cancer Chemother Biol Response Modif 21:791-801. 2003
  8. ncbi request reprint Individualized cancer therapy: molecular approaches to the prediction of tumor response
    Howard L McLeod
    Washington University School of Medicine, Department of Medicine, 660 S Euclid, Campus Box 8069, St Louis, MO 63110, USA
    Expert Rev Anticancer Ther 2:113-9. 2002
  9. ncbi request reprint The thiopurine S-methyltransferase gene locus -- implications for clinical pharmacogenomics
    Howard L McLeod
    Department of Medicine, Washington University School of Medicine, 660 S Euclid Ave Campus Box 8069, St Louis, Missouri 63110, USA
    Pharmacogenomics 3:89-98. 2002
  10. pmc Racial differences in advanced colorectal cancer outcomes and pharmacogenetics: a subgroup analysis of a large randomized clinical trial
    Hanna K Sanoff
    Department of Medicine, Division of Hematology Oncology, University of North Carolina, Chapel Hill, NC 27599 7305, USA
    J Clin Oncol 27:4109-15. 2009

Collaborators

Detail Information

Publications106 found, 100 shown here

  1. ncbi request reprint Pharmacogenetic analysis of clinically relevant genetic polymorphisms
    Howard L McLeod
    Department of Medicine, The Alvin J Siteman Cancer Center, Washington University School of Medicine, St Louis, MO 63110, USA
    Clin Infect Dis 41:S449-52. 2005
    ..Although such an approach has theoretical appeal as a means of enhancing quality and improving outcomes in this setting, several obstacles currently exist and slow the progress toward clinical application...
  2. pmc CYP3A4 and CYP3A5 genotyping by Pyrosequencing
    Adam A Garsa
    Washington University School of Medicine, Department of Medicine, Division of Oncology, St Louis, MO 63110, USA
    BMC Med Genet 6:19. 2005
    ..This study describes Pyrosequencing assays for key SNPs in CYP3A4 (CYP3A4*1B, CYP3A4*2, and CYP3A4*3) and CYP3A5 (CYP3A5*3C and CYP3A5*6)...
  3. ncbi request reprint Using genetic variation to optimize cancer chemotherapy
    Howard L McLeod
    Washington University School of Medicine, Siteman Cancer Center, St Louis, MO 63110, USA
    Clin Adv Hematol Oncol 1:107-11. 2003
    ..This review will discuss recent clinically relevant examples of cancer pharmacogenetics and how genetic differences are helping to shape the future of individualized cancer chemotherapy...
  4. ncbi request reprint Cancer pharmacogenomics: SNPs, chips, and the individual patient
    Howard L McLeod
    Departments of Medicine, Molecular Biology and Pharmacology, and Genetics, Siteman Cancer Center, Washington University School of Medicine, St Louis, Missouri, USA
    Cancer Invest 21:630-40. 2003
    ....
  5. pmc Unfavourable expression of pharmacologic markers in mucinous colorectal cancer
    S C Glasgow
    Department of Surgery, Washington University School of Medicine, St Louis, MI, USA
    Br J Cancer 92:259-64. 2005
    ..Likewise, DFS may be decreased in patients with mucinous tumours who receive 5-FU. The presence of mucin should be carefully evaluated in developmental trials of new agents for treating colorectal cancer...
  6. ncbi request reprint Application of pharmacogenomics in the individualization of chemotherapy for gastrointestinal malignancies
    Howard L McLeod
    Department of Medicine and The Siteman Cancer Center, Washington University School of Medicine, St Louis, MO 63110 1093, USA
    Clin Colorectal Cancer 4:S43-7. 2004
    ....
  7. ncbi request reprint Molecular predictors of prognosis and response to therapy in colorectal cancer
    Howard L McLeod
    Washington University School of Medicine, Department of Medicine, St Louis, MO 63110 1093, USA
    Cancer Chemother Biol Response Modif 21:791-801. 2003
  8. ncbi request reprint Individualized cancer therapy: molecular approaches to the prediction of tumor response
    Howard L McLeod
    Washington University School of Medicine, Department of Medicine, 660 S Euclid, Campus Box 8069, St Louis, MO 63110, USA
    Expert Rev Anticancer Ther 2:113-9. 2002
    ..This review will highlight areas of progress with use of molecular approaches to improve the prediction of tumor response, towards the goal of optimized therapy for each individual patient...
  9. ncbi request reprint The thiopurine S-methyltransferase gene locus -- implications for clinical pharmacogenomics
    Howard L McLeod
    Department of Medicine, Washington University School of Medicine, 660 S Euclid Ave Campus Box 8069, St Louis, Missouri 63110, USA
    Pharmacogenomics 3:89-98. 2002
    ..Recent studies defined target starting doses for mercaptopurine based on TPMT genotypes. This polymorphism is one of the best models for the translation of genomic information to guide patient therapeutics...
  10. pmc Racial differences in advanced colorectal cancer outcomes and pharmacogenetics: a subgroup analysis of a large randomized clinical trial
    Hanna K Sanoff
    Department of Medicine, Division of Hematology Oncology, University of North Carolina, Chapel Hill, NC 27599 7305, USA
    J Clin Oncol 27:4109-15. 2009
    ..A subgroup analysis of a multisite National Cancer Institute-sponsored trial (N9741) was performed comparing outcomes of black and white patients with metastatic CRC receiving uniform treatment...
  11. pmc Ability of VKORC1 and CYP2C9 to predict therapeutic warfarin dose during the initial weeks of therapy
    N S Ferder
    Saint Louis College of Pharmacy, St Louis, MO, USA
    J Thromb Haemost 8:95-100. 2010
    ..Experts have hypothesized that genotype becomes irrelevant once international normalized ratio (INR) values are available because INR response reflects warfarin sensitivity...
  12. ncbi request reprint Cancer pharmacogenomics: current and future applications
    James W Watters
    Department of Medicine, Washington University School of Medicine, 660 S Euclid Ave Campus Box 8069, St Louis, MO 63110, USA
    Biochim Biophys Acta 1603:99-111. 2003
    ..The power and utility of the mouse as an experimental system for pharmacogenomic discovery will also be discussed in the context of cancer therapy...
  13. ncbi request reprint Pharmacogenetic analysis of paclitaxel transport and metabolism genes in breast cancer
    S Marsh
    Department of Medicine, Washington University School of Medicine, St Louis, MO 63110, USA
    Pharmacogenomics J 7:362-5. 2007
    ..Alternatively, the role of CYP1B1 in estrogen metabolism may influence the risk of invasive or paclitaxel resistant breast cancer in patients carrying the CYP1B1*3 allele...
  14. pmc A polymorphism in the VKORC1 regulator calumenin predicts higher warfarin dose requirements in African Americans
    D Voora
    Department of Medicine, Washington University in St Louis, St Louis, Missouri, USA
    Clin Pharmacol Ther 87:445-51. 2010
    ..14, one-sided P = 0.03). CALU rs339097 A>G is associated with higher warfarin dose requirements, independent of known genetic and nongenetic predictors of warfarin dose in African Americans...
  15. pmc A mixture model approach in gene-gene and gene-environmental interactions for binary phenotypes
    Lang Li
    Division of Biostatistics, Department of Medicine, Indiana University, Indianapolis, Indiana46202, USA
    J Biopharm Stat 18:1150-77. 2008
    ..The mixture model approach has the highest recovery probability to recover the true partition in the simulation studies. Its applications are exemplified in interim data analyses for two cancer studies...
  16. ncbi request reprint A phase II study of irinotecan and carboplatin in advanced non-small cell lung cancer with pharmacogenomic analysis: final report
    Giancarlo A Pillot
    Division of Medical Oncology, Department of Internal Medicine, Washington University School of Medicine, St Louis, Missouri 63110, USA
    J Thorac Oncol 1:972-8. 2006
    ..In addition, we studied the correlation between certain genotypes of enzymes involved in irinotecan metabolism with efficacy and toxicity...
  17. doi request reprint Phase I study of biweekly oxaliplatin, gemcitabine and capecitabine in patients with advanced upper gastrointestinal malignancies
    B R Tan
    Division of Medical Oncology, Washington University School of Medicine, St Louis, MO 63110, USA
    Ann Oncol 19:1742-8. 2008
    ..Oxaliplatin, gemcitabine and capecitabine are all active agents against upper gastrointestinal and pancreaticobiliary cancers...
  18. pmc RNA profiling of cyclooxygenases 1 and 2 in colorectal cancer
    R D Church
    1Department of Surgery, Washington University School of Medicine, St Louis, MO 63110 1093, USA
    Br J Cancer 91:1015-8. 2004
    ..We report that Cox-1 and Cox-2 expression is highly variable in Dukes' C tumours, and changes in Cox-1 expression may be of importance...
  19. ncbi request reprint Thymidylate synthase pharmacogenetics in colorectal cancer
    S Marsh
    Washington University School of Medicine, Departments of Medicine, Molecular Biology and Pharmacology, and Genetics, Siteman Cancer Center, St. Louis, MO, USA
    Clin Colorectal Cancer 1:175-8; discussion 179-81. 2001
    ..Prospective confirmation of the impact of TSER on outcome, after TS-targeted chemotherapy, will define the utility of pharmacogenetics to optimize the selection of 5-FU therapy for colorectal cancer...
  20. doi request reprint Irinotecan pharmacogenetics: influence of pharmacodynamic genes
    Janelle M Hoskins
    Department of Internal Medicine, Washington University School of Medicine, St Louis, Missouri, USA
    Clin Cancer Res 14:1788-96. 2008
    ..We undertook a retrospective candidate gene haplotype association study to investigate this hypothesis...
  21. ncbi request reprint Pharmacogenomic assessment of carboxylesterases 1 and 2
    Sharon Marsh
    Department of Medicine, Washington University School of Medicine and the Siteman Cancer Center, St Louis, MO 63110, USA
    Genomics 84:661-8. 2004
    ..Functional analysis of the novel polymorphisms described in this study is now warranted to identify putative roles in drug metabolism...
  22. ncbi request reprint Expression of drug pathway proteins is independent of tumour type
    W Zhang
    Department of Medicine, Washington University School of Medicine, St Louis, MO 63110, USA, and Department of Pathology, Free University Hospital, Amsterdam, The Netherlands
    J Pathol 209:213-9. 2006
    ..Cluster analysis identified a variety of tumours with the same pharmacological profile. The anatomy independence of drug pathways stimulates efforts to move away from our traditional approaches to the selection of cancer therapy...
  23. ncbi request reprint Ethnic differences in pharmacogenetically relevant genes
    R M Engen
    Department of Medicine, Washington University School of Medicine and the Siteman Cancer Center, St Louis, Missouri 63110, USA
    Curr Drug Targets 7:1641-8. 2006
    ..Understanding the influence of ethnicity on pharmacogenomics will allow for comprehensive strategies for using the genome to optimize therapy for patients throughout the world...
  24. ncbi request reprint Genotypes associated with myocardial infarction risk are more common in African Americans than in European Americans
    David E Lanfear
    Washington University School of Medicine, Department of Medicine, St Louis, Missouri 63110 1093, USA
    J Am Coll Cardiol 44:165-7. 2004
    ..This study was designed to describe the frequencies of multiple myocardial infarction (MI) risk-associated genotypes among different racial groups...
  25. ncbi request reprint Single nucleotide polymorphism profiling across the methotrexate pathway in normal subjects and patients with rheumatoid arthritis
    Prabha Ranganathan
    Department of Medicine, Washington University School of Medicine, St Louis, Missouri 63110, USA prangana im wustl edu
    Pharmacogenomics 5:559-69. 2004
    ..Whether such differences contribute to a differential response to MTX in patients with RA deserves to be investigated...
  26. ncbi request reprint Prospective dosing of warfarin based on cytochrome P-450 2C9 genotype
    Deepak Voora
    Department of Medicine, Washington University School of Medicine, St Louis, MO 63110, USA
    Thromb Haemost 93:700-5. 2005
    ..Prospective, perioperative pharmacogenetics-based dosing of warfarin is feasible; however, further evaluation in a randomized, controlled study is recommended...
  27. ncbi request reprint Pharmacogenetic analysis of clinically relevant genetic polymorphisms
    Christine M Rose
    Washington University School of Medicine, St Louis, MO, USA
    Methods Mol Med 85:225-37. 2003
  28. pmc Cancer pharmacogenetics
    S Marsh
    Department of Medicine, Washington University School of Medicine, 660 South Euclid Ave, Campus Box 8069, The Siteman Cancer Center, and the CREATE Pharmacogenetic Research Network, St Louis, MO 63110 1093, USA
    Br J Cancer 90:8-11. 2004
    ..In addition, the need for polygenic pharmacogenomic strategies to identify patients at risk for adverse drug reactions will be highlighted...
  29. ncbi request reprint Polymorphism discovery in 51 chemotherapy pathway genes
    Robert R Freimuth
    Department of Medicine, Washington University School of Medicine, St Louis, MO, USA
    Hum Mol Genet 14:3595-603. 2005
    ..These results provide experimental validation and estimated allele frequencies for polymorphisms in three common ethnic groups and facilitate applied pharmacogenetic studies of anticancer drugs...
  30. ncbi request reprint Pharmacogenomics of cancer chemotherapy-induced toxicity
    C Ryan Miller
    Division of Neuropathology, Department of Pathology and Immunology, Washington University School of Medicine, St Louis, Missouri, USA
    J Support Oncol 5:9-14. 2007
    ..This review will discuss clinically relevant examples of gene polymorphisms that influence toxicity and the experimental tools that have been utilized for discovering toxicity-related polymorphisms...
  31. ncbi request reprint Pyrosequencing of clinically relevant polymorphisms
    Sharon Marsh
    Division of Molecular Oncology, Washington University School of Medicine, St Louis, MO, USA
    Methods Mol Biol 311:97-114. 2005
    ..Assays details for Pyrosequencing of clinically relevant polymorphisms are described in this chapter...
  32. ncbi request reprint Pharmacogenetic influences on treatment response and toxicity in colorectal cancer
    Benjamin R Tan
    Department of Medicine and The Siteman Cancer Center, Washington University School of Medicine, St Louis, MO, USA
    Semin Oncol 32:113-9. 2005
    ..Validation of these predictive factors in prospective clinical trials is now necessary to allow for a rational and systematic individualization of cancer therapy...
  33. ncbi request reprint Beta-2 adrenergic receptor genotypes and haplotypes in different ethnic groups
    Taylor J Maxwell
    Department of Biology, Washington University in St Louis, St Louis, MO 63110 1093, USA
    Int J Mol Med 16:573-80. 2005
    ..Further studies are needed to see if functional relationships are the same across populations...
  34. ncbi request reprint Pharmacogenomics: unlocking the human genome for better drug therapy
    H L McLeod
    Department of Medicine, Division of Oncology, Washington University Medical School, St Louis, Missouri 63110 1093, USA
    Annu Rev Pharmacol Toxicol 41:101-21. 2001
    ..This review highlights the current status of work in this field and addresses strategies that hold promise for future advances in pharmacogenomics...
  35. ncbi request reprint Therapeutic opportunities from tumour biology in metastatic colon cancer
    H L McLeod
    Department of Medicine and Therapeutics, Institute of Medical Sciences, University of Aberdeen, Foresterhill, AB25 2ZD, Aberdeen, UK
    Eur J Cancer 36:1706-12. 2000
    ....
  36. ncbi request reprint Pharmacogenetics of irinotecan toxicity
    Sharon Marsh
    Washington University, School of Medicine, Division of Oncology, 660 South Euclid Avenue, Campus Box 8069, St Louis, MO 63110, USA
    Pharmacogenomics 5:835-43. 2004
    ..Prospective screening of patients prior to chemotherapy selection may reduce the frequency of severe toxicities by allowing alternate therapy selections for patients carrying the UGT1A1*28 polymorphism...
  37. pmc Copy-number analysis of topoisomerase and thymidylate synthase genes in frozen and FFPE DNAs of colorectal cancers
    Jinsheng Yu
    Washington University School of Medicine, Department of Pathology and Immunology, Saint Louis, MO, USA
    Pharmacogenomics 9:1459-66. 2008
    ....
  38. ncbi request reprint Beta2-adrenergic receptor genotype and survival among patients receiving beta-blocker therapy after an acute coronary syndrome
    David E Lanfear
    Departments of Medicine, Genetics, and Molecular Biology and Pharmacology, Washington University School of Medicine, St Louis, MO
    JAMA 294:1526-33. 2005
    ..However, no associations between these polymorphisms and mortality have been demonstrated...
  39. pmc Interaction between PPARA genotype and beta-blocker treatment influences clinical outcomes following acute coronary syndromes
    Sharon Cresci
    Department of Medicine, Washington University School of Medicine, 660 South Euclid Avenue, Campus Box 8086, Saint Louis, MO 63110 1093, USA
    Pharmacogenomics 9:1403-17. 2008
    ....
  40. ncbi request reprint Pharmacogenetics and pediatric cancer
    Lisa Bomgaars
    Department of Medicine, Baylor College of Medicine, Houston, Texas 77030, USA
    Cancer J 11:314-23. 2005
    ....
  41. doi request reprint CANDID: a flexible method for prioritizing candidate genes for complex human traits
    Janna E Hutz
    Division of Statistical Genomics, Washington University School of Medicine, Saint Louis, Missouri, USA
    Genet Epidemiol 32:779-90. 2008
    ..Its accuracy and ease of use make CANDID a highly useful tool in study design and analysis for complex human traits...
  42. ncbi request reprint Pharmacokinetics after endovascular lung perfusion with Cisplatin
    Daniel B Brown
    Mallinckrodt Institute of Radiology, Washington University School of Medicine, 510 South Kingshighway Boulevard, Box 8131, St Louis, Missouri 63110, USA
    J Vasc Interv Radiol 17:883-8. 2006
    ..Endovascular lung perfusion (ELP) is a technique designed to deliver high doses of cisplatin via the pulmonary artery for the treatment of lung tumors. The purpose of the current study was to evaluate variables that affect adduct formation...
  43. ncbi request reprint Methotrexate pharmacogenetics: the first step toward individualized therapy in rheumatoid arthritis
    Prabha Ranganathan
    Division of Rheumatology, Washington University School of Medicine, St Louis, Missouri 63110, USA
    Arthritis Rheum 54:1366-77. 2006
  44. ncbi request reprint Systems pharmacogenomics in yeast
    Patrick Cahan
    Washington University School of Medicine, Department of Medicine, Division of Oncology, Computational Biology Program, St Louis, Missouri 63110, USA
    Pharmacogenomics 7:255-9. 2006
    ..The screens identified genes in well-characterized DNA, in addition to genes whose role in DNA-damage-response pathways had not previously been established...
  45. ncbi request reprint Identification of NR1I2 genetic variation using resequencing
    Cristi R King
    Department of Medicine, Washington University School of Medicine, St Louis, MO, 63110, USA
    Eur J Clin Pharmacol 63:547-54. 2007
    ..This heterodimer binds to the nuclear receptor response elements of downstream genes such as ABCB1, CYP2C, and CYP3A. This study determined the extent of NR1I2 variation in three world populations...
  46. ncbi request reprint Pharmacogenetics and oncology treatment for breast cancer
    Sharon Marsh
    Washington University School of Medicine, Division of Oncology, St Louis, MO 63110, USA
    Expert Opin Pharmacother 8:119-27. 2007
    ..DNA variations in metabolism, transport and drug target genes may contribute to chemotherapy efficacy and toxicities. The status of the identification of genetic markers for breast cancer therapy selection is highlighted in this review...
  47. ncbi request reprint Concordance of pharmacogenetic markers in germline and colorectal tumor DNA
    Sharon Marsh
    Washington University School of Medicine, Campus Box 8069 660 South Euclid AvenueSt Louis, MO 63110, USA
    Pharmacogenomics 6:873-7. 2005
    ..However, this relies on the assumption that germline DNA is representative of the tumor genotype. To date, there has been little attention paid to defining the relationship between tumor and germline genomes...
  48. ncbi request reprint Pharmacogenetic assessment of toxicity and outcome after platinum plus taxane chemotherapy in ovarian cancer: the Scottish Randomised Trial in Ovarian Cancer
    Sharon Marsh
    Washington University School of Medicine, Division of Oncology, St Louis, MO 63110, USA
    J Clin Oncol 25:4528-35. 2007
    ....
  49. ncbi request reprint Methotrexate (MTX) pathway gene polymorphisms and their effects on MTX toxicity in Caucasian and African American patients with rheumatoid arthritis
    Prabha Ranganathan
    Department of Medicine, Washington University School of Medicine, St Louis, Missouri 63110, USA
    J Rheumatol 35:572-9. 2008
    ..We examined the influence of MTX transporter gene polymorphisms on MTX toxicity in 2 racial groups of patients with RA...
  50. pmc A high-resolution map of segmental DNA copy number variation in the mouse genome
    Timothy A Graubert
    Department of Medicine, Division of Oncology, Stem Cell Biology Section, Washington University, St Louis, Missouri, United States of America
    PLoS Genet 3:e3. 2007
    ..Annotation of CNVs in the mouse genome combined with sequence-based analysis provides an important resource that will help define the genetic basis of complex traits...
  51. ncbi request reprint Variance in the expression of 5-Fluorouracil pathway genes in colorectal cancer
    Elizabeth A Kidd
    Department of Medicine, Alvin J Siteman Cancer Center, Washington University School of Medicine, St Louis, Missouri 63110, USA
    Clin Cancer Res 11:2612-9. 2005
    ..These variations in gene expression could provide valuable insights for optimizing treatment selection for patients with colorectal cancer...
  52. ncbi request reprint Pharmacogenomics: the influence of genomic variation on drug response
    Fabienne J Thomas
    Washington University School of Medicine, Department of Medicine, Campus Box 8069, St Louis, MO 63110, USA
    Curr Top Med Chem 4:1399-409. 2004
    ..This review will discuss clinically relevant examples of genetic polymorphisms that influence the outcome of drug therapy, and possibilities for future applications of pharmacogenomics...
  53. ncbi request reprint Distribution of ITPA P32T alleles in multiple world populations
    Sharon Marsh
    Division of Oncology, Washington University School of Medicine, 660 South Euclid Avenue, Campus Box 8069, St Louis, MO 63110, USA
    J Hum Genet 49:579-81. 2004
    ..This data provides a foundation on which prospective screening studies can be planned to identify patients at risk for severe toxicity from azathioprine therapy...
  54. ncbi request reprint Phase II study of docetaxel and irinotecan in metastatic or recurrent esophageal cancer: a preliminary report
    Ramaswamy Govindan
    Department of Medicine, Washington University School of Medicine, St Louis, Missouri, USA
    Oncology (Williston Park) 17:27-31. 2003
    ..However, this combination chemotherapy regimen has an unacceptable rate of febrile neutropenia. This regimen needs to be modified to reduce the incidence of febrile neutropenia...
  55. ncbi request reprint Use of pyrosequencing to detect clinically relevant polymorphisms in dihydropyrimidine dehydrogenase
    Ranjeet Ahluwalia
    Washington University School of Medicine, Division of Oncology, St Louis, MO 63110, USA
    Clin Chem 49:1661-4. 2003
  56. pmc Genome-wide discovery of loci influencing chemotherapy cytotoxicity
    James W Watters
    Department of Medicine, Siteman Cancer Center, Washington University School of Medicine, 660 South Euclid Avenue, Campus Box 8069, St Louis, MO 63110, USA
    Proc Natl Acad Sci U S A 101:11809-14. 2004
    ....
  57. ncbi request reprint DNA repair pathway profiling and microsatellite instability in colorectal cancer
    Jinsheng Yu
    Department of Medicine, Washington University School of Medicine and Siteman Cancer Center, Saint Louis, Missouri 63110 1093, USA
    Clin Cancer Res 12:5104-11. 2006
    ..DNA repair is conducted by distinct pathways of genes, many of which are thought to be altered in colorectal cancer. However, there has been little characterization of these pathways in colorectal cancer...
  58. ncbi request reprint Use of pharmacogenetics and clinical factors to predict the maintenance dose of warfarin
    Brian F Gage
    Department of Medicine, Washington University School of Medicine Campus Box 8005, 660 S Euclid Ave St Louis, Missouri 63110, USA
    Thromb Haemost 91:87-94. 2004
    ..001). In conclusion, the maintenance warfarin dose can be estimated from demographic, clinical, and pharmacogenetic factors that can be obtained at the time of warfarin initiation...
  59. ncbi request reprint Challenges of implementing pharmacogenetics in the critical care environment
    Bradley D Freeman
    Department of Surgery, Washington University School of Medicine, 660 S Euclid Avenue, Box 8109, St Louis, Missouri 63110, USA
    Nat Rev Drug Discov 3:88-93. 2004
  60. ncbi request reprint Analysis of variation in mouse TPMT genotype, expression and activity
    James W Watters
    Department of Medicine, Washington University School of Medicine, 660 South Euclid Avenue, St Louis, MO 63110, USA
    Pharmacogenetics 14:247-54. 2004
    ..In addition, the identified pattern of low haplotype diversity suggests that the mouse is likely to be useful for pharmacogenomic discovery by associating haplotype blocks with drug response phenotypes among inbred strains...
  61. ncbi request reprint Frequency of compound genotypes associated with beta-blocker efficacy in congestive heart failure
    David E Lanfear
    Washington University School of Medicine, Department of Medicine, 660 S Euclid Ave, Campus Box 8069, St Louis, MO 63110 1093, USA
    Pharmacogenomics 5:553-8. 2004
    ..This study provides the first look into the population frequency of these compound genotypes, and it provides the necessary first step for future evaluation of polygenic strategies to individualize therapy for heart failure...
  62. ncbi request reprint Use of pharmacogenetics to guide warfarin therapy
    Deepak Voora
    Departments of Medicine and Pathology, Washington University School of Medicine, St Louis, Missouri 63110, USA
    Drugs Today (Barc) 40:247-57. 2004
    ..The genotype assays for genetic variants relevant to warfarin are widely used and are being developed for commercial use (5), making the promise of a pharmacogenetics-based approach a near reality...
  63. ncbi request reprint Endovascular lung perfusion using high-dose cisplatin: uptake and DNA adduct formation in an animal model
    Daniel B Brown
    Mallinckrodt Institute of Radiology, Alvin J Siteman Cancer Center, St Louis, MO 63110, USA
    Oncol Rep 11:237-43. 2004
    ..Further study of ELP evaluating the acute and chronic effects of repeated treatment administration is warranted...
  64. ncbi request reprint Interethnic variability of ERCC2 polymorphisms
    C R King
    Department of Medicine, Division of Oncology, Washington University School of Medicine, Saint Louis, MO 63110, USA
    Pharmacogenomics J 5:54-9. 2005
    ..This information on ERCC2 genomic structure will allow the construction of definitive studies to clarify the clinical role of this important gene...
  65. pmc Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin
    B F Gage
    Department of Internal Medicine, Washington University School of Medicine, St Louis, Missouri, USA
    Clin Pharmacol Ther 84:326-31. 2008
    ..To facilitate use of these pharmacogenetic and clinical algorithms, we developed a nonprofit website, http://www.WarfarinDosing.org...
  66. ncbi request reprint Pharmacogenomics: from bedside to clinical practice
    Sharon Marsh
    Division of Oncology, Washington University School of Medicine, St Louis, MO 63110, USA
    Hum Mol Genet 15:R89-93. 2006
    ..This review describes some of the recent advances in pharmacogenomics research...
  67. ncbi request reprint Global pharmacogenetics: giving the genome to the masses
    Sharon Marsh
    Washington University School of Medicine, Department of Medicine, Room 1021 CSRB NT, 660 South Euclid Avenue, Campus Box 8069, St Louis, MO 63110, USA
    Pharmacogenomics 7:625-31. 2006
    ..The PharmacoGenetics for Every Nation Initiative is a first step to making pharmacogenetics applicable on a global level...
  68. ncbi request reprint CEPH individuals are representative of the European American population: implications for pharmacogenetics
    Melissa A Meucci
    Washington University School of Medicine, Department of Medicine, St Louis, MO, USA
    Pharmacogenomics 6:59-63. 2005
    ..These data support the usefulness of the CEPH panel in pharmacogenetic discovery efforts for European-derived populations...
  69. ncbi request reprint PolyMAPr: programs for polymorphism database mining, annotation, and functional analysis
    Robert R Freimuth
    Department of Medicine, Washington University School of Medicine, St Louis, Missouri 63110, USA
    Hum Mutat 25:110-7. 2005
    ..PolyMAPr can be obtained from http://pharmacogenomics.wustl.edu...
  70. ncbi request reprint SNP databases and pharmacogenetics: great start, but a long way to go
    Sharon Marsh
    Department of Medicine, Washington University School of Medicine, St Louis, Missouri, USA
    Hum Mutat 20:174-9. 2002
    ....
  71. ncbi request reprint Differential expression of the AP-1 transcription factor family members in human colorectal epithelial and neuroendocrine neoplasms
    Wanghai Zhang
    Department of Medicine, Washington University School of Medicine, St Louis, MO 63110 1093, USA
    Am J Clin Pathol 124:11-9. 2005
    ..Up-regulation of c-Jun and Fra-1 is an early event in human colorectal tumorigenesis. Overexpression of Fra-2 may participate in tumor progression...
  72. ncbi request reprint The pharmacogenetics of coumarin therapy
    Deepak Voora
    Washington University School of Medicine, Departments of Medicine and of Pathology, St Louis, MO 63110, USA
    Pharmacogenomics 6:503-13. 2005
    ..A comprehensive pharmacogenetics approach to warfarin therapy has the potential to improve the safety and efficiency of warfarin initiation...
  73. ncbi request reprint A mouse-based strategy for cyclophosphamide pharmacogenomic discovery
    James W Watters
    Washington Univ School of Medicine, Dept of Medicine, Campus Box 8069, St Louis, MO 63110, USA
    J Appl Physiol 95:1352-60. 2003
    ..This phenotypic and genotypic variation among inbred strains provides a framework for cyclophosphamide pharmacogenomic discovery...
  74. ncbi request reprint Gene expression profiling of the irinotecan pathway in colorectal cancer
    Jinsheng Yu
    Department of Medicine, Division of Biostatistics, Washington University School of Medicine, 660 South Euclid Avenue, Saint Louis, MO 63110, USA
    Clin Cancer Res 11:2053-62. 2005
    ..Our study indicates that gene expression profiling could be valuable for predicting tumor response to chemotherapy and for tailoring therapy to individual cancer patients...
  75. ncbi request reprint Lessons learned from the irinotecan metabolic pathway
    M K Ma
    Washington University School of Medicine, Department of Medicine, St Louis, MO 63110, USA
    Curr Med Chem 10:41-9. 2003
    ....
  76. ncbi request reprint Cyclo-oxygenase 2 inhibition in colorectal cancer therapy
    R D Church
    Department of Surgery, Washington University School of Medicine, 660 South Euclid Avenue, Campus Box 8069, St Louis, MO 63110 1093, USA
    Br J Surg 90:1055-67. 2003
    ..These drugs have implications for both the prevention of colorectal carcinoma and the potential treatment of the disease...
  77. ncbi request reprint Hydroxychloroquine for the prevention of acute graft-versus-host disease after unrelated donor transplantation
    H Khoury
    Division of Oncology, Section of Leukemia and Bone Marrow, Washington University School of Medicine, St Louis, Missouri 63110, USA
    Biol Blood Marrow Transplant 9:714-21. 2003
    ..An ongoing placebo-controlled randomized trial will further determine what role HCQ plays in preventing GVHD after allografting...
  78. ncbi request reprint Pharmacogenetics in rheumatology: the prospects and limitations of an emerging field
    C Siva
    Department of Medicine, Washington University School of Medicine, St Louis, MO 63110, USA
    Rheumatology (Oxford) 41:1273-9. 2002
    ..To review the fundamental concepts of pharmacogenetics and analyse how the broad principles of this rapidly emerging field may influence the treatment of rheumatic disease in future...
  79. ncbi request reprint PromoLign: a database for upstream region analysis and SNPs
    Tao Zhao
    Department of Genetics, Washington University School of Medicine, St Louis, Missouri 63110, USA
    Hum Mutat 23:534-9. 2004
    ..PromoLign could be applied to a variety of SNPs and transcription related studies, including association genetics, population genetics, and pharmacogenetics...
  80. ncbi request reprint Pharmacogenomic discovery approaches: will the real genes please stand up?
    Richard A Walgren
    Department of Medicine, Washington University School of Medicine, 660 S Euclid Ave, Campus Box 8069, St Louis, MO 63110, USA
    J Clin Oncol 23:7342-9. 2005
    ..This review will place in context clinically relevant pharmacogenomic discovery approaches, including the relative strengths and weaknesses and the challenges inherent with achieving the goal of individualized therapy...
  81. pmc Will pharmacogenetics allow better prediction of methotrexate toxicity and efficacy in patients with rheumatoid arthritis?
    P Ranganathan
    Division of Rheumatology and Department of Medicine, Washington University School of Medicine, 660 S Euclid Avenue, St Louis, MO 63110, USA
    Ann Rheum Dis 62:4-9. 2003
    ..However, a significant number of patients with RA either do not benefit from the drug or are unable to tolerate it. Pharmacogenetic approaches may help optimise treatment with MTX, and also other agents, in RA...
  82. ncbi request reprint Strategies for enzyme/prodrug cancer therapy
    G Xu
    Department of Medicine, Washington University School of Medicine, 660 South Euclid Avenue, St. Louis, MO 63110, USA
    Clin Cancer Res 7:3314-24. 2001
    ..In this article, disadvantages and advantages associated with each approach (GDEPT, VDEPT, and ADEPT) and future perspective for improving current systems are discussed...
  83. pmc Phase I study of pegylated liposomal doxorubicin and the multidrug-resistance modulator, valspodar
    P M Fracasso
    Alvin J Siteman Cancer Center and the Department of Medicine, Washington University School of Medicine, St Louis, MO 63110, USA
    Br J Cancer 93:46-53. 2005
    ..009). Treatment with PEG-LD 25 mg m(-2) in combination with valspodar results in a moderate prolongation of total doxorubicin clearance and half-life but did not increase the toxicity of this agent...
  84. ncbi request reprint Current overview of pharmacogenetics
    Howard L McLeod
    Washington University, St Louis, MO, USA
    Clin Adv Hematol Oncol 2:205-7. 2004
  85. ncbi request reprint ABCB1 2677G>T/A genotype and paclitaxel pharmacogenetics in ovarian cancer
    Sharon Marsh
    Clin Cancer Res 12:4127; author reply 4127-9. 2006
  86. ncbi request reprint The candidate oncogene ZNF217 is frequently amplified in colon cancer
    Patrick H Rooney
    Department of Pathology, University of Aberdeen, UK
    J Pathol 204:282-8. 2004
    ..There was a trend toward poorer survival in patients whose cancers had either gain or loss of ZNF217...
  87. ncbi request reprint A novel polymorphism of human CYP2A6 gene CYP2A6*17 has an amino acid substitution (V365M) that decreases enzymatic activity in vitro and in vivo
    Tatsuki Fukami
    Drug Metabolism and Toxicology, Division of Pharmaceutical Sciences, Graduate School of Medical Science, Kanazawa University, Kanazawa 920 1192, Japan
    Clin Pharmacol Ther 76:519-27. 2004
    ..5 +/- 10.5, n = 37). A subject with CYP2A6*17 / CYP2A6*17 revealed the lowest cotinine/nicotine ratio (1.8). We found a novel allele in black subjects that affects the nicotine metabolism in vitro and in vivo...
  88. ncbi request reprint Cancer pharmacogenomics: DNA genotyping and gene expression profiling to identify molecular determinants of chemosensitivity
    J Todd Auman
    UNC Institute for Pharmacogenomics and Individualized Therapy, Chapel Hill, North Carolina 27599 7360, USA
    Drug Metab Rev 40:303-15. 2008
    ..This review focuses on pharmacogenomics studies conducted to gain insight into the molecular determinants of chemosensitivity to cancer chemotherapeutics...
  89. ncbi request reprint Pharmacogenetics goes 3D
    Howard L McLeod
    Nat Genet 37:794-5. 2005
  90. ncbi request reprint Thymidine phosphorylase and capecitabine: a predictive marker for therapy selection?
    BERT H O'NEIL
    J Clin Oncol 24:4051-3. 2006
  91. ncbi request reprint Characterization of novel CYP2A6 polymorphic alleles (CYP2A6*18 and CYP2A6*19) that affect enzymatic activity
    Tatsuki Fukami
    Drug Metabolism and Toxicology, Division of Pharmaceutical Sciences, Graduate School of Medical Science, Kanazawa University, Kakuma machi, Kanazawa 920 1192, Japan
    Drug Metab Dispos 33:1202-10. 2005
    ....
  92. ncbi request reprint Irinotecan pathway genotype analysis to predict pharmacokinetics
    Ron H J Mathijssen
    Department of Medical Oncology, Erasmus MC Daniel den Hoed Cancer Center, 3075 EA Rotterdam, The Netherlands
    Clin Cancer Res 9:3246-53. 2003
    ..The purpose was to explore the relationships between irinotecan disposition and allelic variants of genes coding for adenosine triphosphate binding cassette transporters and enzymes of putative relevance for irinotecan...
  93. ncbi request reprint ABCG2 pharmacogenetics: ethnic differences in allele frequency and assessment of influence on irinotecan disposition
    Floris A de Jong
    Department of Medical Oncology, Erasmus University MC Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
    Clin Cancer Res 10:5889-94. 2004
    ..The aim of this study was to evaluate the ethnic distribution and potential functional consequence of the ABCG2 421C>A genotype in cancer patients treated with irinotecan...
  94. ncbi request reprint Pharmacogenetics of tipifarnib (R115777) transport and metabolism in cancer patients
    Alex Sparreboom
    Clinical Pharmacology Research Core, National Cancer Institute, Bethesda, MD, USA
    Invest New Drugs 22:285-9. 2004
    ..15). Overall, this study indicates that ABCB1 genotype might be correlated with tipifarnib pharmacokinetics, although considerable overlap in exposure measures between genotype groups was observed...
  95. ncbi request reprint Comprehensive evaluation of variability in nicotine metabolism and CYP2A6 polymorphic alleles in four ethnic populations
    Miki Nakajima
    Department of Drug Metabolism and Toxicology, Division of Pharmaceutical Sciences, Graduate School of Medical Science, Kanazawa University, Kakuma machi, Kanazawa, Japan
    Clin Pharmacol Ther 80:282-97. 2006
    ..This comprehensive study of 4 populations extends our understanding of nicotine metabolism and the impact of genetic polymorphisms of the CYP2A6 gene...
  96. ncbi request reprint New developments in the epidemiology of cancer prognosis: traditional and molecular predictors of treatment response and survival
    Christine B Ambrosone
    Department of Epidemiology Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY 14263, USA
    Cancer Epidemiol Biomarkers Prev 15:2042-6. 2006
  97. ncbi request reprint Diflomotecan pharmacokinetics in relation to ABCG2 421C>A genotype
    Alex Sparreboom
    Medical Oncology Clinical Research Unit, National Cancer Institute, Bethesda, MD 20892, USA
    Clin Pharmacol Ther 76:38-44. 2004
    ..We performed an exploratory analysis to evaluate the effects of the natural allelic variant ABCG2 421C>A on the pharmacokinetics of diflomotecan...
  98. ncbi request reprint Gene expression profiles and molecular markers to predict recurrence of Dukes' B colon cancer
    Yixin Wang
    Veridex, LLC, a Johnson and Johnson Company, 3210 Merryfield Row, San Diego, CA 92121, USA
    J Clin Oncol 22:1564-71. 2004
    ..In this study, we used DNA chip technology to systematically identify new prognostic markers for tumor relapse in Dukes' B patients...
  99. ncbi request reprint Therapeutic synergy between irinotecan and 5-fluorouracil against human tumor xenografts
    Rami G Azrak
    Department of Pharmacology and Therapeutics, Grace Cancer Drug Center, Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY 14263, USA
    Clin Cancer Res 10:1121-9. 2004
    ..Studies were carried out to define the optimal dosage, sequence, and timing for the combination in mice bearing xenografted human tumors...
  100. ncbi request reprint Disposition of 9-nitrocamptothecin and its 9-aminocamptothecin metabolite in relation to ABC transporter genotypes
    William C Zamboni
    Hillman Cancer Research Center, Molecular Therapeutics Drug Discovery Program, University of Pittsburgh Cancer Institute, Pittsburgh, PA 15213, USA
    Invest New Drugs 24:393-401. 2006
    ..The aim of this study was to evaluate the functional consequence of known single nucleotide polymorphisms in the transporter genes ABCB1, ABCC2, and ABCG2 on the pharmacokinetic disposition of 9NC and 9AC...
  101. ncbi request reprint Association of CYP2C8, CYP3A4, CYP3A5, and ABCB1 polymorphisms with the pharmacokinetics of paclitaxel
    Anja Henningsson
    Department of Pharmaceutical Biosciences, Faculty of Pharmacy, Uppsala University, Uppsala, Sweden
    Clin Cancer Res 11:8097-104. 2005
    ..To retrospectively evaluate the effects of six known allelic variants in the CYP2C8, CYP3A4, CYP3A5, and ABCB1 genes on the pharmacokinetics of the anticancer agent paclitaxel (Taxol)...